Immuron Ltd revenue

Immuron Ltd's revenue was $5.2m in fiscal 2026, up 10.9% on the year before. Since fiscal 2016 ($729,653) it has grown at a compound 21.8% a year.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Immuron Ltd: revenue history, annual
Fiscal year	2016Jun 2016	2017Jun 2017	2018Jun 2018	2019Jun 2019	2020Jun 2020	2021Jun 2021	2022Jun 2022	2023Jun 2023	2024Jun 2024	2025Jun 2025	2026Jun 2026
Revenue	730	1,053	1,129	1,442	1,690	109	555	1,215	3,214	4,721	5,238
Growth on the year before	—	+44.4%	+7.2%	+27.7%	+17.2%	−93.6%	+409.8%	+118.8%	+164.6%	+46.9%	+10.9%
Gross profit	510	799	1,104	1,230	1,228	71	380	881	2,188	3,087	3,378
Gross margin	69.9%	75.8%	97.8%	85.3%	72.6%	65.0%	68.4%	72.5%	68.1%	65.4%	64.5%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Immuron Ltd	$5.2m	10.9%	—
Inventiva S.a.	$5.1m	-49.1%	—
Taysha Gene Therapies, Inc.	$5.5m	-32.3%	—
Adlai Nortye Group Ltd.	$5.0m	—	—
Rani Therapeutics Holdings, Inc.	$4.9m	306.4%	—
Bolt Biotherapeutics, Inc.	$4.7m	12.8%	—

Compare with peers

Head to head: IMRN vs IVA IMRN vs TSHA ANL vs IMRN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Immuron Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Immuron Ltd.